Browsing Bergen Open Research Archive by Author "Torgauten, Hilde Marie"
Now showing items 1-3 of 3
-
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, The Trung; Schikora-Rustad, Stine; Vaage, Eline Benno; Mygland, Åse Daasvand; Wergeland, Stig; Aarseth, Jan Harald; Aaberge, Ingeborg Sundsvalen; Torkildsen, Øivind; Holmøy, Trygve; Berge, Tone; Myhr, Kjell-Morten; Harbo, Hanne-Cathrin Flinstad; Andersen, Jan Terje; Munthe, Ludvig Andre; Søraas, Arne Vasli; Celius, Elisabeth Gulowsen; Vaage, John T.; Lund-Johansen, Fridtjof; Nygaard, Gro Owren (Journal article; Peer reviewed, 2021)Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective ... -
Predictors of hospitalization due to infection in rituximab-treated MS patients
Karlowicz, Jakob Rishovd; Klakegg, Mattias; Aarseth, Jan Harald; Bø, Lars; Myhr, Kjell-Morten; Torgauten, Hilde Marie; Torkildsen, Øivind; Wergeland, Stig (Journal article; Peer reviewed, 2023)Background: Rituximab is extensively used off-label to treat multiple sclerosis (MS), and long-term vigilance for adverse events is needed. This study was conducted to determine frequencies and predictors of hematological ... -
Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig; Bø, Lars; Aarseth, Jan Harald; Torkildsen, Øivind (Journal article; Peer reviewed, 2021-01-31)Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy ...